

SAFETY DATA SHEET



Losartan Formulation



Version 3.11 Revision Date: 23.03.2020 SDS Number: 19366-00016 Date of last issue: 13.09.2019
Date of first issue: 07.10.2014

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Losartan Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33nd floor
Jersey City, New Jersey, U.S.A 07302

Telephone : 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION

GHS Classification

Acute toxicity (Oral) : Category 4

Serious eye damage/eye irritation : Category 1

Skin sensitisation : Category 1

Reproductive toxicity : Category 1B

Effects on or via lactation

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Blood, Cardio-vascular system, Stomach, Kidney)

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H302 Harmful if swallowed.
H317 May cause an allergic skin reaction.
H318 Causes serious eye damage.
H360D May damage the unborn child.
H362 May cause harm to breast-fed children.
H373 May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated ex-

SAFETY DATA SHEET



Losartan Formulation



Version 3.11 Revision Date: 23.03.2020 SDS Number: 19366-00016 Date of last issue: 13.09.2019
Date of first issue: 07.10.2014

posure if swallowed.

Precautionary statements :

Prevention:

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P263 Avoid contact during pregnancy/ while nursing.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P272 Contaminated work clothing should not be allowed out of the workplace.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.
P302 + P352 IF ON SKIN: Wash with plenty of water.
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 30 -< 50
Losartan	124750-99-8	>= 30 -< 50
Starch	9005-25-8	>= 10 -< 20

4. FIRST AID MEASURES

SAFETY DATA SHEET



Losartan Formulation



Version 3.11 Revision Date: 23.03.2020 SDS Number: 19366-00016 Date of last issue: 13.09.2019
Date of first issue: 07.10.2014

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention immediately.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.
- Most important symptoms and effects, both acute and delayed : Harmful if swallowed.
May cause an allergic skin reaction.
Causes serious eye damage.
May damage the unborn child.
May cause harm to breast-fed children.
May cause damage to organs through prolonged or repeated exposure if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.
-

5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Chlorine compounds
Nitrogen oxides (NO_x)
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.

SAFETY DATA SHEET



Losartan Formulation



Version 3.11 Revision Date: 23.03.2020 SDS Number: 19366-00016 Date of last issue: 13.09.2019
Date of first issue: 07.10.2014

Special protective equipment for firefighters : Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Losartan Formulation

Version 3.11 Revision Date: 23.03.2020 SDS Number: 19366-00016 Date of last issue: 13.09.2019
Date of first issue: 07.10.2014

- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	PEL (long term)	10 mg/m ³	SG OEL
		TWA	10 mg/m ³	ACGIH
Losartan	124750-99-8	TWA	100 µg/m ³ (OEB 2)	Internal
Starch	9005-25-8	PEL (long term)	10 mg/m ³	SG OEL
		TWA	10 mg/m ³	ACGIH

- Engineering measures** : Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
- Eye protection : Wear the following personal protective equipment:
Chemical resistant goggles must be worn.
If splashes are likely to occur, wear:
Face-shield
- Skin and body protection : Select appropriate protective clothing based on chemical

SAFETY DATA SHEET



Losartan Formulation



Version 3.11 Revision Date: 23.03.2020 SDS Number: 19366-00016 Date of last issue: 13.09.2019
Date of first issue: 07.10.2014

Hygiene measures : resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).
: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : White to light yellow

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : 1 g/cm³

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

SAFETY DATA SHEET



Losartan Formulation



Version 3.11 Revision Date: 23.03.2020 SDS Number: 19366-00016 Date of last issue: 13.09.2019
Date of first issue: 07.10.2014

Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
 Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Minimum ignition energy : > 300 mJ
Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.
Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,502 mg/kg
Method: Calculation method

Components:

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

SAFETY DATA SHEET



Losartan Formulation



Version 3.11 Revision Date: 23.03.2020 SDS Number: 19366-00016 Date of last issue: 13.09.2019
Date of first issue: 07.10.2014

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Losartan:

Acute oral toxicity : LD50 (Mouse): 1,257 - 1,590 mg/kg

LDLo (Rat): 200 mg/kg

LDLo (Mouse): 400 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Losartan:

Species : Rabbit
Result : Mild skin irritation

Serious eye damage/eye irritation

Causes serious eye damage.

Components:

Losartan:

Species : Rabbit
Result : Severe irritation

Starch:

Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Components:

Losartan:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Assessment : Probability or evidence of skin sensitisation in humans

Losartan Formulation

Version 3.11 Revision Date: 23.03.2020 SDS Number: 19366-00016 Date of last issue: 13.09.2019
Date of first issue: 07.10.2014

Result : positive

Starch:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Losartan:

Genotoxicity in vitro : Test Type: in vitro assay
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster ovary cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

Test Type: Chromosomal aberration
Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration
Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Carcinogenicity

Not classified based on available information.

Losartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	23.03.2020	19366-00016	Date of first issue: 07.10.2014

Components:**Cellulose:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	72 weeks
Result	:	negative

Losartan:

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	92 weeks
Dose	:	200 mg/kg body weight
Result	:	negative

Species	:	Rat
Application Route	:	Oral
Exposure time	:	105 weeks
Dose	:	270 mg/kg body weight
Result	:	negative

Reproductive toxicity

May damage the unborn child.
May cause harm to breast-fed children.

Components:**Cellulose:**

Effects on fertility	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
----------------------	---	---

Effects on foetal development	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative
-------------------------------	---	--

Losartan:

Effects on fertility	:	Test Type: Fertility Species: Rat, female Application Route: Oral Fertility: LOAEL: 200 mg/kg body weight Result: female reproductive effects Remarks: Maternal toxicity observed.
----------------------	---	---

Effects on foetal development	:	Test Type: Development Species: Rabbit Application Route: Oral General Toxicity Maternal: NOAEL: 10 mg/kg body weight Developmental Toxicity: NOAEL F1: 20 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, No
-------------------------------	---	--

Losartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	23.03.2020	19366-00016	Date of first issue: 07.10.2014

teratogenic effects

Test Type: Development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: LOAEL: 10 mg/kg body weight
 Result: Fetotoxicity, No teratogenic effects

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

Studies indicating a hazard to babies during the lactation period

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

Components:**Losartan:**

Exposure routes : Ingestion
 Target Organs : Blood, Cardio-vascular system, Stomach, Kidney
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Cellulose:**

Species : Rat
 NOAEL : >= 9,000 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Losartan:

Species : Rat
 LOAEL : 15 mg/kg
 Application Route : Oral
 Exposure time : 309 d
 Number of exposures : daily
 Target Organs : Blood, Kidney, Cardio-vascular system, Stomach

Species : Dog
 NOAEL : 5 mg/kg
 Application Route : Oral
 Exposure time : 1 Months
 Symptoms : Salivation, Vomiting

Species : Dog

Losartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	23.03.2020	19366-00016	Date of first issue: 07.10.2014

LOAEL	:	25 mg/kg
Application Route	:	Oral
Exposure time	:	53 Weeks
Number of exposures	:	daily
Symptoms	:	Salivation, Vomiting

Starch:

Species	:	Rat
NOAEL	:	>= 2,000 mg/kg
Application Route	:	Skin contact
Exposure time	:	28 Days
Method	:	OECD Test Guideline 410

Aspiration toxicity

Not classified based on available information.

Components:**Losartan:**

No aspiration toxicity classification

Experience with human exposure**Components:****Losartan:**

Eye contact	:	Symptoms: Eye irritation
Ingestion	:	Symptoms: hypotension, tachycardia

12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
		Exposure time: 48 h
		Remarks: Based on data from similar materials

Losartan:

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 929 mg/l
		Exposure time: 96 h
		Method: FDA 4.11

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 331 mg/l
		Exposure time: 48 h
		Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants	:	NOEC (Microcystis aeruginosa (blue-green algae)): 949 mg/l
		Exposure time: 10 d
		Method: FDA 4.01

SAFETY DATA SHEET



Losartan Formulation



Version 3.11 Revision Date: 23.03.2020 SDS Number: 19366-00016 Date of last issue: 13.09.2019
Date of first issue: 07.10.2014

NOEC (Selenastrum capricornutum (green algae)): 143 mg/l
Exposure time: 10 d
Method: FDA 4.01

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 10 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 100 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Losartan:

Stability in water : Hydrolysis: < 10 %(5 d)

Bioaccumulative potential

Components:

Losartan:

Partition coefficient: n-octanol/water : log Pow: 1.2

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

SAFETY DATA SHEET



Losartan Formulation



Version 3.11 Revision Date: 23.03.2020 SDS Number: 19366-00016 Date of last issue: 13.09.2019
Date of first issue: 07.10.2014

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and : Not applicable
Environmental Protection and Management (Hazardous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials) : Not applicable
Regulations

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
SG OEL : Singapore. Workplace Safety and Health Act - First Schedule Permissible Exposure Limits of Toxic Substances

ACGIH / TWA : 8-hour, time-weighted average
SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule;

SAFETY DATA SHEET



Losartan Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	23.03.2020	19366-00016	Date of first issue: 07.10.2014

ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN